Sunday, September 24, 2023
Advances in
The treatment of patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer is rapidly evolving. Recent approvals of mechanistic target of rapamycin (mTOR) inhibitors and cyclin dependent kinase (CDK) 4/6 inhibitors have the potential to change the treatment armamentarium for this patient population and ultimately improve outcomes. Clinicians are faced with increasingly complex decision-making and must be educated on the optimal use of these agents in clinical practice.
Supported by an independent educational grant from
See All
Download slides with the latest data on CDK4/6 inhibitors in breast cancer.
Download
Breast cancer Read article
Cancer treatment reviews Read article
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial Read article
The Role of CDK 4/6 Inhibitors in Breast Cancer Treatment. Read article
The Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib in Combination With Letrozole Versus Letrozole Alone as First-Line Treatment of Oestrogen Receptor-Positive, HER2-Negative, Advanced Breast Cancer (PALOMA-1/TRIO-18): A Randomised Phase 2 Study. Read article
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. Read article
Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer. Read article
Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3). Read article
Quality of Life With Palbociclib Plus Fulvestrant in Previously Treated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Patient-Reported Outcomes From the PALOMA-3 Trial. Read article
ESMO Clinical Practice Guidelines: Breast Cancer Read article
European Society of Breast Cancer Specialists Read article
European Cancer Organization Read article
Targeting CDK4/6 in Patients With Cancer. Read article
Profile of Palbociclib in the Treatment of Metastatic Breast Cancer. Read article
See All
Steering Committee Chair
Professor, Breast Center, Department of Obstetrics and Gynecology, University of Munich (LMU), Munich, Germany
Head, Breast Cancer and Gynecological Tumours, Ramón y Cajal University Hospital, Oncology Department, Madrid; Clinical Investigator, Breast Cancer Research Program, Vall d’Hebron Institute of Oncology, Barcelona, Spain
Head, Medical Oncology Unit; Chair, Oncology Department, "Sandro Pitigliani" Medical Oncology Unit - Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy
Professor of Breast Cancer Medicine, Royal Marsden Hospital, London, United Kingdom
Professor, J Minjoz University Hospital, Besancon, France
Professor, Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
Steering Committee Chair
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Pfizer Inc.
Served as a speaker or a member of a speakers bureau for: Novartis Pharmaceuticals Corporation; Pfizer Inc
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Biothera Pharmaceuticals, Inc.; Celgene Corporation; Cellestia Biotech; Roche
Served as a speaker or a member of a speakers bureau for: Celgene Corporation; Eisai Co., Ltd; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Roche
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Bayer HealthCare Corporation; Celgene Corporation; Eisai Co., Ltd; Genomic Health; Ipsen; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Pierre Fabre; Roche
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Puma Biotechnology; Roche
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; GlaxoSmithKline; Pfizer Inc.; Puma Biotechnology
Received grants for clinical research from: GlaxoSmithKline; Pfizer Inc.
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: Amgen Inc.; Novartis Pharmaceuticals Corporation; Roche
Served as a speaker or a member of a speaker's bureau for: Eisai Co., Ltd; Novartis Pharmaceuticals Corporation; Roche
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: AstraZeneca; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Roche
Discuss With Your Peers
What is the best sequence for using cyclin-dependent kinase (CDK)4/6 inhibitors?